Green Cross is Japan's largest pharmaceutical company.
Green Cross Corporation was founded in 1950 as Japan's first commercial blood banks and became a diversified international pharmaceutical company producing ethical drugs for delivery or administration by doctors and healthcare workers. The company merged into Yoshitomi Pharmaceutical Co., Ltd. on April 1, 1998. Its products were extensively used in the treatments of a wide range of ailments. As well as supplying whole blood for transfusions, Green Cross was also active in developing blood derivative products such as coagulation factors, immunoglobulin and albumin. In the mid 1960's, it expanded into the non-plasma sector. Cardiovascular agents, coagulation/fibrinolytic agents, immunological agents, anti-inflammatory agents, albumin-based agents, blood plasma components and parenteral nutrition accounted for 71% of fiscal 1998 unconsolidated revenues; wholesale of diagnostic reagents, 14% and other, 15%. Unconsolidated revenues accounted for 59.5% of fiscal 1998 consolidated revenues. The company had eleven consolidated subsidiaries, three each in the United States and Japan, and one each in Germany, the United Kingdom, Barbados, China and Hong Kong. Overseas sales accounted for 41.9% of fiscal 1998 consolidated revenues.
GREEN CROSS CORPORATION (THE) PEOPLE:
* President - KAZUNARI DOI
* Senior Managing Director - KEIZO KUNOH
* Senior Managing Director - ETSUJI ODA
